Symcel Expands Workforce for Clinical Growth

Symcel is expanding its workforce to bring its patented technology to the clinical antimicrobial susceptibility testing (AST) markets. The technology, called calScreener, is a cell-based assay tool for real-time cell metabolism measurements. 

The company says it is a key time in its strategic development and, with an increased global focus, Symcel forecasts that calScreener will become the gold standard for combination testing of antibiotics against multi-resistant bacteria within the next five years. The method has already established significant sales and research projects amongst scientific and clinical key opinion leaders in the antimicrobial resistance and antimicrobial susceptibility testing fields.

Symcel is also currently leveraging the Horizon 2020 funded Phase II (AST) project – in which multi-resistant bacterial infections will be clinically validated using Symcel’s sensitive screening method. To head this study, Dr. Marta Veses Garcia was hired as Symcel’s new application scientist, and will lead the experimental work within the Horizon 2020 project together with scientific partners. Dr. Karin Gillner joins as a project manager tasked with running the Horizon 2020 project including from an innovation management perspective. She has over 15 years experience of research, project management and coordination of multicenter studies. Lastly, Pelle Friberg joins Symcel as its sales lead and will work closely with executives on the company’s sales and marketing strategy. 

“We are very pleased to welcome Marta Veses Garcia, Karin Gillner and Pelle Friberg to the company at this exciting time in its development. We look forward to utilising their respective skills and working closely with them all as we clinically validate our innovative technology in AST and initiate our five-year plan to enter and expand into the clinical space.” said Jesper Ericsson, chief executive officer of Symcel.

The new hires will facilitate the advanced expertise of the company’s senior executives ultimately responsible for driving the company’s corporate and scientific development.